Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04894591 · ClinicalTrials.gov registry record
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
A clinical trial of Extensive-stage Small-cell Lung Cancer, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 272
- Enrollment target
- 20
- Study locations
NCT04894591 is a study of Extensive-stage Small-cell Lung Cancer that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 272 participants, above the 165-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04894591, a study of Extensive-stage Small-cell Lung Cancer, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Conditions Studied
Interventions
- DRUG Zepzelca
Study Locations (20)
Florida
- ASCLEPES Research Centers - Brooksville
- Woodlands Medical Specialists - Woodlands Center For Specialized Medicine - Pensacola
Kansas
- Stormont-Vail Cancer Center-Stormont-Vail Healthcare - Cotton-O'Neil Cancer Center - Topeka
- Cancer Center of Kansas - Wichita
Kentucky
- Baptist Health Lexington - Lexington
- Pikeville Medical Center - Leonard Lawson Cancer Center - Pikeville
New York
- Center for Clinical Research-Rochester General Hospital - Rochester
- Montefiore Medical Center (MMC) - Montefiore Medical Park (MMP) - The Bronx
Alabama
- Clearview Cancer Institute - Huntsville
Connecticut
- Eastern Connecticut Hematology and Oncology - Norwich
Illinois
- Mid-Illinois Hematology & Oncology Associates - Normal
Indiana
- Goshen Health Center for Cancer Care - Goshen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2025-06-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04894591
The ClinicalTrials.gov registry entry for NCT04894591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (65% higher). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zepzelca is the first listed.
NCT04894591 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Kansas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04894591 about?
NCT04894591 is a clinical study titled "To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)". To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
What is the current status of trial NCT04894591?
This trial is currently completed. The enrollment target is 272 participants. The study started on 2021-06-28. Estimated completion is 2025-06-04.
What conditions does trial NCT04894591 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT04894591?
The interventions under investigation include: Zepzelca (DRUG).
Who is sponsoring clinical trial NCT04894591?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04894591 being conducted?
This trial has 20 study locations across Alabama, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
-
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
RECRUITING · Phase 2
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.